Login
Companies $IMNM
$17.69 +$0.08 (0.45%) After hours
Immunome Inc. logo

Immunome Inc.

immunome.com

What Do They Do?

Develops targeted cancer medicines, including oral therapies, antibody-drug conjugates and radioligand therapies, for people with cancer.

Who Are Their Customers?

AbbVie paid Immunome under a collaboration agreement that ended in July 2025.

Do Revenues Turn Into Profits?

No. It lost $212.4M in FY2025.

Operating income, FY2025
−3229% of revenue
▲ +27% (Loss) vs FY2024 (−$305.8M, −3382%)
Net income, FY2025
−3060% of revenue
▲ +28% (Loss) vs FY2024 (−$293M, −3240%)
Free cash flow, FY2025
−2890% of revenue
▼ −70% (Loss) vs FY2024 (−$118M, −1305%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −49% (Loss)
vs −$57.5M in Q3 FY2025
  • Oct 2, 2026 Immunome acquired varegacestat patent rights and ended BMS milestone and royalty payments The amendment assigned patent rights previously licensed to Immunome; consideration included $20.0 million in cash and 4,425,487 shares.

From antibody discovery to targeted cancer therapies The older report describes a memory B-cell platform for discovering antibody treatments, including an infectious-disease program. The latest report centers on targeted oncology therapies, with antibody-drug conjugates and other cancer drug candidates.

Who Do They Compete With?

Competes with Merck and CStone Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support